Recarbrio

Chemical Nameimipenem, cilastatin, and relebactam
Dosage FormInjectable (intravenous; 1.25 g/vial)
Drug ClassInhibitors
SystemUrinary, Digestive
CompanyMerck & Co.
Approval Year2019

Indication

  • Recarbrio is indicated in patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of the following infections caused by susceptible gram-negative bacteria: complicated urinary tract infections, including pyelonephritis, and complicated intra-abdominal infections.
Last updated on 10/15/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?